Medical Device Manufacturing & R&D Summit: Pioneering the Future of Healthcare Technology

We are pleased to announce the highly anticipated Medical Device Manufacturing & R&D Summit, set to take place on October 12-13 at the state-of-the-art Cosmopolitan in Las Vegas. Hosted by marcus evans, a leading innovator in the healthcare industry, this exclusive summit will bring together key stakeholders, thought leaders, and experts from the medical device sector to share insights, foster collaborations, and drive advancements in healthcare technology.

The Medical Device Manufacturing & R&D Summit is designed to be a premier gathering for professionals and organizations at the forefront of medical device research, development, and manufacturing. This event aims to provide a platform for knowledge exchange, showcasing cutting-edge technologies, and facilitating networking opportunities among industry peers.

Key Highlights of the Summit:

Esteemed Speakers: Attendees will have the privilege of hearing from renowned experts and visionaries who have made significant contributions to the medical device industry. They will share their expertise and insights during keynote presentations and engaging panel discussions.

Emerging Trends and Innovations: The summit will explore the latest advancements in medical device manufacturing, research, and development. Topics will include Regulatory Updates, Supply chain, innovation, and more.

Networking Opportunities: The summit will facilitate networking sessions, allowing attendees to connect with potential partners, suppliers, and collaborators, fostering collaborations that drive innovation in the sector.

1:1 meetings: Meetings set prior to coming onsite ensuring everyone’s time is used efficiently and effectively during the 2 days at the event

Registration for the Medical Device Manufacturing & R&D Summit is now open at https://bit.ly/3O1WhQn

For sponsorship and partnership opportunities, please contact Leyana Daccache at leyanad@marcusevanscy.com

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”